On September 15, 2026, XPENG-W (09868.HK) traded weaker in the afternoon. As of 14:45, the stock was quoted at HK$40.40, down 3.86%.
on 15 September 2026, AI chip stocks traded with volatility while ASMPT (00522.HK) strengthened. As of 14:19, the company quoted HKD 154.400, up 0.06%.
on 15 September 2026, humanoid robot stocks traded with volatility while MIDEA GROUP (00300.HK) strengthened. As of 13:47, the company quoted HKD 100.400, up 0.40%.
as of 09:49 on September 15, 2026, the CNI Consumer Electronics Theme Index (931494) rose 0.74%, with constituent stock SYTECH up 5.48%, and E Fund CSI Consumer Electronic Theme ETF (562950) last quoted at RMB 1.5.In terms of units outstanding, E Fund CSI Consumer Electronic Theme ETF saw its units grow by 19.00 million over the past two weeks, a significant increase.In terms of capital flows, E Fund CSI Consumer Electronic Theme ETF recorded a latest net capital inflow of RMB 2.987 million. Over a longer horizon, the fund saw net capital inflows on 6 of the past 10 trading days, absorbing a combined RMB 31.1629 million, with average daily net inflows reaching RMB 3.1163 million.
On 15 September 2026, CCTECH (300604.SZ) announced that the twentieth meeting of the fourth session of its board of directors held on 14 September 2026 considered and approved the resolutions relating to the issue of H Shares and listing on The Stock Exchange of Hong Kong Limited, and that the Company intends to issue H Shares and apply for listing on the Main Board of the Hong Kong Stock Exchange.
On 15 September 2026, GENFLEET-B (02595.HK) announced that updated Phase II data of GFH375 monotherapy in previously treated KRAS G12D-mutant NSCLC were presented at the 2026 World Conference on Lung Cancer, with a confirmed objective response rate of 52.1%.
On 15 September 2026, UNISOUND (09678.HK) announced the launch of U2-Flash, a new-generation high-density intelligent model whose DeepSWE v1.1 score doubled from the previous generation to 64.6.
On 14 September 2026, GAC GROUP (02238.HK) announced that it signed a letter of intent with FAW to acquire part of FAW's equity interest in a whole-vehicle joint venture company by issuing A shares and to raise matching funds. Upon completion FAW will become the Company's second largest shareholder with strategic influence, and the transaction is expected to constitute a major asset restructuring and a related party transaction under the rules of the Shanghai Stock Exchange. Trading in the Company's A shares (601238) has been suspended from the opening of the market on 14 September 2026 for an expected period of not more than 10 A-share trading days, while trading in its H shares was suspended from 9:30 a.m. on 14 September and the Company has applied to resume trading from 9:00 a.m. on 15 September.
On 15 September 2026, BIOHEART-B (02185.HK) announced that it recently entered into a strategic cooperation agreement with Shanghai Shenqi Medical Technology Co., Ltd. to jointly advance the commercialisation and clinical application of the BioHeart bioresorbable rapamycin-eluting coronary stent system. The agreement is a framework agreement and is non-binding, and as of the date of the announcement the two parties had not entered into a formal or legally binding agreement, so the cooperation may or may not materialise.
On 14 September 2026, RUIHE DATA (03680.HK) announced that its wholly-owned subsidiary Ruihe Data Technology (Hong Kong) Limited submitted a subscription application for shares allocated to it under the international offering of Ligent Technologies, Inc. (09856.HK) at an offer price of HKD 32.96 per share, with the subscription amount not exceeding HKD 60,000,000. The subscription constitutes a discloseable transaction, and completion is subject to the successful listing of Ligent Technologies' international offering shares and the results of the share allocation.
On 14 September 2026, Guangdong Tianyu Semiconductor Co., Ltd. (02658.HK) announced that its Board approved an H share repurchase plan under the general mandate granted by shareholders on 19 May 2026, covering up to 5,899,042 H shares, or 10% of the issued H shares as at the date the mandate was granted, with the repurchase price not exceeding the average closing price over the preceding five trading days by 5% or more.
On 14 September 2026, OneRobotics (Shenzhen) Co., Ltd. (06600.HK) announced that the trustee of its 2026 H Share Incentive Scheme purchased a further 101,200 H shares on the market between 28 August and 14 September 2026 at approximately HKD 39.48 to approximately HKD 53.00 per share, for a total consideration of approximately HKD 5.0 million; following the purchase, the trustee holds 653,200 H shares, representing approximately 0.290% of the total issued H shares.
On 14 September 2026, BOAN BIOTECH (06955.HK) announced that the investigational new drug application for its PD-1/IL-2 antibody-cytokine prodrug BA1203 has been approved by the Centre for Drug Evaluation of the National Medical Products Administration of the PRC, with the drug intended for the treatment of multiple solid tumours.
On 14 September 2026, WEIHAI BANK (09677.HK) announced that the Bank has successfully issued its 2026 green financial bonds (first tranche) in the national interbank bond market, with an issue size of RMB 500 million, a coupon rate of 1.65% and a term of three years.
On 14 September 2026, HENGRUI PHARMA (01276.HK) announced that its subsidiary Beijing Shengdi Pharmaceutical Co., Ltd. received a Notice of Acceptance from the National Medical Products Administration, with the marketing application for SHR-2004 injection, a Class 1 innovative drug and coagulation factor XI monoclonal antibody, accepted for the proposed indication of preventing venous thromboembolism in adult patients undergoing elective knee replacement surgery, under acceptance number CXSS2600151.
On 14 September 2026, YIDU TECH (02158.HK) announced that Yidu Cloud (Beijing) Technology Co., Ltd., an affiliate of the Company, received a notice of award and won the bid for the ageing and health innovation translation construction project of the National Clinical Medical Research Centre for Geriatric Diseases of Xiangya Hospital of Central South University, with a total project amount of approximately RMB 3,565,000.
